RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > Regulatory Manager: What Senior Management Needs to Know About CMC Regulatory Compliance for Biotec

Regulatory Manager: What Senior Management Needs to Know About CMC Regulatory Compliance for Biotech Products Part 1: Initiating Phase 1 Clinical Trials

Posted 01 August 2009 | By

Biotechnology-derived pharmaceuticals are being developed by many companies whose senior management teams have varying degrees of familiarity or experience with the regulatory requirements for these challenging products. A 2006 independent study of the US Food and Drug Administration's (FDA) drug approval review process concluded that biotech startups and first-product biotech companies were especially at risk of failing to achieve their goal of market approval:

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe